10 July 2008: Following the closing of the subscription period of NorDiag`s rights issue Wednesday 9 July 2008, the Board of NorDiag approved the allotment of shares on the same day. The following primary insiders and related parties of such have subscribed and been allotted shares at NOK 2 in the share issue:

- Chairman of the Board Hans Hekland: Hannibal Invest AS (private investment company) 15,000 shares. Total new shareholding: 37,672 shares. Sarsia Innovation AS (Hans Hekland CEO) 250,000 shares. Total new shareholding: 492,673 shares. Sarsia Life Science Fund AS (Hans Hekland CEO) 5 000 000 shares. Total new shareholding: 11,210,661 shares. Novel Diagnostics ASA (Hans Hekland chairman) 201,000 shares. Total new shareholding: 4,046,660 shares.

- CEO Mårten Wigstøl: Barracuda Invest AS (private investment company) 125,000 shares. Total new shareholding: 196,055 shares. Mårten Wigstøl holds in addition 500,000 share options.

- Chief Scientific Officer Erik Hornes 25,000 shares. Total new shareholding: 71,155 shares. Erik Hornes holds in addition 500,000 share options.

- CFO Tone Kvåle 50,000 shares. Total new shareholding: 50,000 shares. Tone Kvåle holds in addition 300,000 share options.

- Sales and Marketing Director Dagfinn Strømme 25,000 shares. Total new shareholding: 35,678 shares. Dagfinn Strømme holds in addition 150,000 share options.

- COO Åse Wikshåland 32,500 shares. Total new shareholding: 42,889 shares. Åse Wikshåland holds in addition 150,000 share options.

- Quality Assurance Director Turid Engen 7,500 shares. Total new shareholding: 7,500. Turid Engen holds in addition 150,000 share options.

- Medical Director Dagfinn Øgreid: Colon AS (private investment company) 500,000 shares. Total new shareholding: 1,154,654 shares.

- President of NorDiag AB Anders Holmberg 25,000 shares. Total new shareholding: 759,655 shares. Anders Holmberg holds in addition 100,000 share options.

- Board Member Ann-Kristin Hageløkken: Biovekst AS (Ann-Kristin Hageløkken, CEO) 442,000 shares. Total new shareholding: 2,665,606 shares.

Contact:
CEO Mårten Wigstøl
Phone: +47 911 65775

About NorDiag:
NorDiag is a biotechnology company developing, manufacturing and marketing of automated solutions, instruments and tests, for diagnostic of infectious diseases and cancer. The Company`s core competence is isolation of bacterial and human DNA from difficult clinical samples, and the Company has established a solid market share in the Scandinavian market for sexually transmitted infections.

The company has similar applications for Tuberculosis and MRSA. An application for respiratory pathogens is under development. NorDiag is also developing a test that shall contribute to early diagnosis of colorectal cancer, as well as a test that shall contribute to optimal treatment of lung cancer patients. NorDiag was founded in 2003 and has its headquarters in Oslo - Norway. The company has offices and laboratories in Bergen - Norway, Stockholm - Sweden and West Chester (PA) - USA. The group has 34 employees. NorDiag is listed on Oslo Stock Exchange with the ticker NORD.

For further information - www.nordiag.com

Read the Notice in Norwegian here